It ain’t coming back. We won’t hangout in a conference room to drink Diet Coke and brainstorm SWOTs. We won’t be presenting (or enduring) dog-and-pony pitches anytime soon. I wouldn’t…
Author: Sander Flaum
Sander Flaum is a veteran advisor to Fortune 500 pharmaceutical companies. He is an acknowledged business leader, marketing and sales effectiveness coach, motivational speaker, and best-selling author.
After COVID-19 – What’s next?
Originally published: MedAdNewsWhen Haven, the much-ballyhooed joint venture of Amazon, Berkshire Hathaway, and JPMorgan Chase, was put out of its misery earlier this year, experts couldn’t wait to voice their opinions.…
Are “greedy” pharmacies endangering our health?
The New York Times recently published (January 31, 2020) what it doubtlessly considers a damning indictment of big box pharmacies (“How Chaos at Chain Drug Stores Is Putting Patients at Risk.”) The article provides…
Seven ideas to help you jump your revenue curve and thrive!
In a few months COVID-19 has transformed the healthcare industry. It is now clear that pharmaceutical manufacturers, and our allies in diagnostics and devices, represent the world’s best defense against this and…
Are you ready for the next big thing? (Hint: you may not like it!)
Tectonic changes are coming to U.S. Pharma. The first shock came in early 2018, when a brash group of healthcare providers announced that they had had enough of capricious, often…
Instead of worrying about drug costs, let’s worry about the cost of drugs that don’t work!
n the closing days of 2019, the U.S. House of Representatives narrowly passed legislation that would, among other things, allow Medicare to refuse to pay for specific drugs it deemed…